LT3723807T - Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą - Google Patents

Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą

Info

Publication number
LT3723807T
LT3723807T LTEPPCT/EP2018/084432T LTEP2018084432T LT3723807T LT 3723807 T LT3723807 T LT 3723807T LT EP2018084432 T LTEP2018084432 T LT EP2018084432T LT 3723807 T LT3723807 T LT 3723807T
Authority
LT
Lithuania
Prior art keywords
pyrasol
pyrides
combination treatments
treatments including
combination
Prior art date
Application number
LTEPPCT/EP2018/084432T
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Mauro Marigo
Paulo Vital
Mikkel JESSING
Morten LANGGÅRD
Lars Rasmussen
Carl CLEMENTSON
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of LT3723807T publication Critical patent/LT3723807T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/EP2018/084432T 2017-12-14 2018-12-12 Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą LT3723807T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700708 2017-12-14
PCT/EP2018/084432 WO2019115566A1 (en) 2017-12-14 2018-12-12 Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines

Publications (1)

Publication Number Publication Date
LT3723807T true LT3723807T (lt) 2021-12-10

Family

ID=64959282

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/084432T LT3723807T (lt) 2017-12-14 2018-12-12 Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą

Country Status (27)

Country Link
US (1) US11634416B2 (lt)
EP (1) EP3723807B1 (lt)
JP (1) JP7261801B2 (lt)
KR (1) KR20200099154A (lt)
CN (1) CN111465410B (lt)
AR (1) AR113931A1 (lt)
AU (1) AU2018385453B2 (lt)
BR (1) BR112019016815A2 (lt)
CA (1) CA3085201A1 (lt)
CL (1) CL2020001548A1 (lt)
CO (1) CO2020007129A2 (lt)
CY (1) CY1124751T1 (lt)
ES (1) ES2899868T3 (lt)
HR (1) HRP20211784T1 (lt)
HU (1) HUE057202T2 (lt)
IL (1) IL275290B2 (lt)
LT (1) LT3723807T (lt)
MX (1) MX2020006174A (lt)
PL (1) PL3723807T3 (lt)
PT (1) PT3723807T (lt)
RS (1) RS62551B1 (lt)
RU (1) RU2020118913A (lt)
SG (1) SG11202005361RA (lt)
SI (1) SI3723807T1 (lt)
SM (1) SMT202100655T1 (lt)
WO (1) WO2019115566A1 (lt)
ZA (1) ZA202003514B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
MX2020006174A (es) 2017-12-14 2022-09-27 H Lundbeck As Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
MXPA06014699A (es) 2004-07-05 2007-03-26 Astellas Pharma Inc Derivados de pirazolo-piridina.
EP1802621B1 (en) * 2004-10-19 2009-05-06 SmithKline Beecham (Cork) Limited Crf receptor antagonists and methods relating thereto
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
RU2402549C3 (ru) 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. Пиперазин-замещенные бензотиофены для лечения психических расстройств
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
ATE545417T1 (de) 2007-03-14 2012-03-15 Ranbaxy Lab Ltd Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
PL2603523T3 (pl) 2010-08-12 2016-07-29 Lilly Co Eli Przeciwciała przeciwko peptydowi amyloidu beta N3pGlu i ich zastosowania
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP3107897A1 (en) 2014-02-19 2016-12-28 H. Lundbeck A/S 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
CA2961186A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
WO2016147659A1 (en) 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
AU2016305275A1 (en) 2015-08-12 2018-02-08 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
WO2017100276A1 (en) 2015-12-08 2017-06-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
CN108369267B (zh) 2015-12-09 2022-06-28 福特全球技术公司 用于遗留移动装置的警告
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
MX2020006174A (es) 2017-12-14 2022-09-27 H Lundbeck As Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
TW201927784A (zh) * 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN111511742B (zh) * 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶

Also Published As

Publication number Publication date
HRP20211784T1 (hr) 2022-02-18
CY1124751T1 (el) 2022-07-22
AU2018385453B2 (en) 2024-02-08
AU2018385453A1 (en) 2020-07-02
JP7261801B2 (ja) 2023-04-20
KR20200099154A (ko) 2020-08-21
RS62551B1 (sr) 2021-12-31
JP2021506775A (ja) 2021-02-22
WO2019115566A1 (en) 2019-06-20
SMT202100655T1 (it) 2022-01-10
ZA202003514B (en) 2022-12-21
SI3723807T1 (sl) 2022-01-31
US20200385381A1 (en) 2020-12-10
US11634416B2 (en) 2023-04-25
BR112019016815A2 (pt) 2020-04-07
MX2020006174A (es) 2022-09-27
EP3723807B1 (en) 2021-10-20
CO2020007129A2 (es) 2020-06-19
CA3085201A1 (en) 2019-06-20
EP3723807A1 (en) 2020-10-21
CN111465410A (zh) 2020-07-28
AR113931A1 (es) 2020-07-01
IL275290A (en) 2020-07-30
PT3723807T (pt) 2021-11-26
HUE057202T2 (hu) 2022-04-28
CN111465410B (zh) 2022-10-25
SG11202005361RA (en) 2020-07-29
CL2020001548A1 (es) 2020-09-25
IL275290B2 (en) 2023-06-01
PL3723807T3 (pl) 2022-01-24
RU2020118913A (ru) 2022-01-14
ES2899868T3 (es) 2022-03-15

Similar Documents

Publication Publication Date Title
EP3636507C0 (en) SAFETY MODEL OF SENSITIVITY, RESPONSIBILITY AND COMFORT
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
EP3661918A4 (en) ANALOGUES OF 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE
EP3551285C0 (en) DEFIBRILLATOR
EP3463464A4 (en) ASSOCIATION TREATMENT
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
SG11201707240SA (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
EP3713931C0 (en) 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE
EP3655436C0 (en) SERUM ALBUMIN BINDING PROTEINS
ZA201606794B (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
LT3402782T (lt) 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
EP3666970A4 (en) SYNTHETIC LEATHER
EP3718330A4 (en) MEETING KEY STRUCTURE
LT3402785T (lt) 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
EP3541931A4 (en) COMBINED FRACTAL TREATMENT
LT3723807T (lt) Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą
IL260536B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP3620471A4 (en) ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE
GB201701315D0 (en) Novel treatments
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
EP3452037A4 (en) METHODS OF TREATMENT WITH CB2 RECEPTOR AGONISTS
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
EP3712139A4 (en) TETRAHYDROISOXAZOLO [4,3-C] PYRIDINE ANTI-HBV COMPOUNDS
HUE054832T2 (hu) Pirido-imidazo rifamicinszármazékok baktériumellenes szerként